[go: up one dir, main page]

PT1212300E - SERUM-PROTEASE INHIBITORS OF AZACICLOALCANONE - Google Patents

SERUM-PROTEASE INHIBITORS OF AZACICLOALCANONE

Info

Publication number
PT1212300E
PT1212300E PT00963388T PT00963388T PT1212300E PT 1212300 E PT1212300 E PT 1212300E PT 00963388 T PT00963388 T PT 00963388T PT 00963388 T PT00963388 T PT 00963388T PT 1212300 E PT1212300 E PT 1212300E
Authority
PT
Portugal
Prior art keywords
sup
sub
methylene
ethylene
alkyl
Prior art date
Application number
PT00963388T
Other languages
Portuguese (pt)
Inventor
Scott C Miller
Juan Jose Marug N S Nchez
Kristin D Haslow
Jonathan P Hall
Original Assignee
Dimensional Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dimensional Pharm Inc filed Critical Dimensional Pharm Inc
Publication of PT1212300E publication Critical patent/PT1212300E/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

The present invention is directed to non-peptidic factor Xa inhibitors which are useful for the treatment of arterial and venous thrombotic occlusive disorders, inflammation, cancer, and neurodegenerative diseases. The factor Xa inhibitors provide compounds having Formula I: or pharmaceutically acceptable salts thereof; wherein Q is phenyl, benzyl, pyridyl, thienyl, indolyl, quinolinyl, benzothienyl, biphenylyl, or imidazolyl; any of which can include one or more optional substituents independently selected from halo, trifluoromethyl, hydroxy, amino, nitro, cyano, C<SUB>1 </SUB>alkoxy, C<SUB>1-3 </SUB>alkyl, methylenedioxy, carboxamido, acetamido, or amidino; X is methylene, carbonyl, or sulfonyl; Z is methylene, ethylene, or propylene; M is methylene or ethylene; and R<SUP>1 </SUP>R<SUP>2 </SUP>and R<SUP>3 </SUP>are independently hydrogen or C<SUB>1-3 </SUB>alkyl.
PT00963388T 1999-09-13 2000-09-13 SERUM-PROTEASE INHIBITORS OF AZACICLOALCANONE PT1212300E (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15323699P 1999-09-13 1999-09-13

Publications (1)

Publication Number Publication Date
PT1212300E true PT1212300E (en) 2004-03-31

Family

ID=22546339

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00963388T PT1212300E (en) 1999-09-13 2000-09-13 SERUM-PROTEASE INHIBITORS OF AZACICLOALCANONE

Country Status (20)

Country Link
US (2) US6469029B1 (en)
EP (1) EP1212300B1 (en)
JP (1) JP2003509409A (en)
KR (1) KR20020027639A (en)
CN (1) CN1373755A (en)
AT (1) ATE253558T1 (en)
AU (1) AU7480800A (en)
BR (1) BR0013926A (en)
CA (1) CA2384247A1 (en)
DE (1) DE60006407T2 (en)
DK (1) DK1212300T3 (en)
ES (1) ES2209987T3 (en)
HK (1) HK1050005A1 (en)
IL (1) IL148358A0 (en)
MX (1) MXPA02002657A (en)
NO (1) NO322753B1 (en)
NZ (1) NZ517603A (en)
PL (1) PL354265A1 (en)
PT (1) PT1212300E (en)
WO (1) WO2001019795A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI288745B (en) 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
WO2002060894A2 (en) 2001-01-30 2002-08-08 Bristol-Myers Squibb Company Sulfonamide lactam inhibitors of factor xa
WO2002094787A1 (en) * 2001-05-23 2002-11-28 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
GB0127568D0 (en) 2001-11-16 2002-01-09 Glaxo Group Ltd Chemical compounds
PT1569912E (en) 2002-12-03 2015-09-15 Pharmacyclics Llc 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
JPWO2009096198A1 (en) * 2008-02-01 2011-05-26 一般社団法人ファルマIp New biaryl derivatives
CN103910688B (en) * 2013-01-04 2016-05-25 陈春麟 2-propyl group-4-chloro-quinazoline derivative and its preparation method and application

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5385885A (en) 1988-01-15 1995-01-31 Gasic; Gregory P. Inhibition of smooth muscle cell proliferation by antistasin and tick anticoagulant peptide
DE4121947A1 (en) 1991-07-03 1993-01-07 Basf Ag 2- (3- (4-AMIDINO-PHENYL)) - PROPIONIC ACID DERIVATIVES, THEIR PRODUCTION AND USE
CA2075154A1 (en) * 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
WO1994020535A1 (en) 1992-12-11 1994-09-15 Corvas International, Inc. ECOTIN AS A FACTOR Xa, XIa, AND XIIa INHIBITOR
US5703208A (en) 1994-06-17 1997-12-30 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors
JPH10503176A (en) 1994-06-17 1998-03-24 コーバス インターナショナル, インコーポレイテッド 3-Amino-2-oxo-1-piperidineacetic acid derivatives as enzyme inhibitors
EP0835109A4 (en) * 1995-06-27 1999-02-03 Merck & Co Inc PYRIDINONE-BASED THROMBIN INHIBITORS
JPH09165370A (en) * 1995-10-13 1997-06-24 Fuji Yakuhin Kogyo Kk Lactam derivative and its salt
PL328307A1 (en) 1996-02-13 1999-01-18 Akzo Nobel Nv Serinic protease inhibitors
JP2000512616A (en) 1996-02-22 2000-09-26 メルク エンド カンパニー インコーポレーテッド Pyridinone thrombin inhibitor
EP0906091B1 (en) 1996-03-29 2006-10-04 Ortho-McNeil Pharmaceuticals, Inc. Amidinohydrazones as protease inhibitors
JP2001504810A (en) 1996-10-11 2001-04-10 シーオーアール・セラピューティックス・インコーポレーテッド Selective factor Xa inhibitor
NZ502876A (en) 1997-08-11 2001-11-30 Cor Therapeutics Inc Fused bicyclic lactam selective factor Xa inhibitors for treating thrombosis related diseases
EP0994892A1 (en) 1997-08-11 2000-04-26 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
EA004180B1 (en) 1997-11-26 2004-02-26 3-Дименшенл Фамэсьютикэлс, Инк. Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors

Also Published As

Publication number Publication date
US20030109517A1 (en) 2003-06-12
HK1050005A1 (en) 2003-06-06
EP1212300A1 (en) 2002-06-12
PL354265A1 (en) 2003-12-29
JP2003509409A (en) 2003-03-11
BR0013926A (en) 2002-07-23
CN1373755A (en) 2002-10-09
DE60006407D1 (en) 2003-12-11
IL148358A0 (en) 2002-09-12
AU7480800A (en) 2001-04-17
ES2209987T3 (en) 2004-07-01
MXPA02002657A (en) 2002-10-28
WO2001019795A1 (en) 2001-03-22
DK1212300T3 (en) 2004-03-15
NO322753B1 (en) 2006-12-04
KR20020027639A (en) 2002-04-13
NO20021224D0 (en) 2002-03-12
US6469029B1 (en) 2002-10-22
EP1212300B1 (en) 2003-11-05
NZ517603A (en) 2003-09-26
CA2384247A1 (en) 2001-03-22
DE60006407T2 (en) 2004-09-09
ATE253558T1 (en) 2003-11-15
NO20021224L (en) 2002-05-13
US6962942B2 (en) 2005-11-08

Similar Documents

Publication Publication Date Title
EA199900591A1 (en) NITROGEN-CONTAINING HETEROAROMATIC COMPOUNDS AS INHIBITOR FACTOR XA
DE69924135D1 (en) HETEROCYCLIC KALIUM CHANNEL INHIBITORS
ATE361748T1 (en) 1-(4-SULFAMYLPHENYL)-3-TRIFLUORMETHYL-5-ARYL-2-PYRAZOLINE AS CYCLOOXYGENASE-2 INHIBITORS
NO20020214L (en) Substituted oxoazaheterocyclyl compounds
WO2001019828A3 (en) Kinase inhibitors as therapeutic agents
TR200001279T2 (en) Poly (ADP-ribose) polymerase (&#34;PARP&#34;) inhibitors, methods and pharmaceutical compositions for the treatment of neural and cardiovascular tissue damage.
DE60019347D1 (en) INHIBITORS OF ALPHA-L BETA-2 MEDIATED CELL ADHESION
EA200300306A1 (en) SPYROPYRIMIDIN-2,4,6-TRIONE METALPROTEINASE INHIBITORS
HN2002000028A (en) METALOPROTEINASH INHIBITING PYRIMIDINS
DE69919212D1 (en) AROMATIC AMIDES
ATE241621T1 (en) ARYLSULFONYLS AS FACTOR XA INHIBITORS
ECSP045104A (en) LIGANDS OF THE CANNABINOID RECEIVERS
PT1212300E (en) SERUM-PROTEASE INHIBITORS OF AZACICLOALCANONE
DE69937372D1 (en) PIPERIDINE-INDOL DERIVATIVES WITH 5-HT6 AFFINITY
HK1045644A1 (en) Antibacterial compound
SE9902267D0 (en) New compounds
EA200000204A1 (en) Pyrrolopyrlonone derivatives as ELASTASIS INHIBITORS NEUTROPHILS
ATE203905T1 (en) THROMBIN INHIBITOR
BR9912374A (en) Isoquinolines as urokinase inhibitors
WO2003064378A3 (en) Novel compounds that inhibit factor xa activity
DK1049670T3 (en) Azetidine carboxamide derivatives for the treatment of CNS disorders
DE69811734D1 (en) CARBOXYLIC ACID SUBSTITUTED HETEROCYCLIC COMPOUNDS AS METALLOPROTEINASE INHIBITORS
FI940171A0 (en) Ketorolac derivatives, whose gastrointestinal irritation and ulceration have been markedly reduced
ATE265453T1 (en) DIKETOPIPERAZINE DERIVATIVES AS THROMBIN INHIBITORS
MX9709386A (en) ARYLSULFONYLAMINOBENZENE DERIVATIVES AND THE USE THEREOF AS FACTOR Xa INHIBITORS.